ELAB News & Events

PMGC Holdings announced the initiation of a preclinical study for EL-32, an engineered probiotic candidate being developed by its wholly owned subsidiary, NorthStrive Biosciences. The study is designed to evaluate EL-32's potential to preserve lean muscle mass while promoting fat loss, both as a standalone therapy and in combination with GLP-1 weight loss treatments. This announcement follows the Company's January 30, 2025 press release titled "NorthStrive Biosciences, a Subsidiary of PMGC Holdings, Signs Agreement for Preclinical Mouse Study of EL-32, a Potential Breakthrough Obesity Therapy Targeting Fat Loss and Muscle Preservation in Combination with GLP-1." Since that announcement, NorthStrive Biosciences has worked on locating material for the study, and study planning with the contract research organization, CRO, finalized the study design, and established the operational timeline and budget required to initiate the program.

PMGC Holdings Inc trading halted, news pending

NorthStrive Biosciences, a wholly owned subsidiary of PMGC Holdings, announced the filing of ten new U.S. patent applications expanding its proprietary EL-22 and EL-32 technologies into animal health and agricultural markets, including applications designed to encourage animals to grow new muscle and increase muscle weight return per animal. These ten patent applications include five new patent applications covering EL-22 and five new, corresponding applications covering EL-32 across multiple farmed animal categories, including livestock, aquaculture, and poultry.